{"commentary":{"count":347,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":130,"x_thread":122,"podcast":86,"x_video":9},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04784715\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04784715","nct_id":"NCT04784715","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04784715. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Trastuzumab deruxtecan (T-DXd) plus pertuzumab-matching placebo","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Trastuzumab deruxtecan (T-DXd) plus pertuzumab","label":"Arm B","type":"EXPERIMENTAL"},{"description":"Standard of care (Taxane (paclitaxel or docetaxel), trastuzumab, and pertuzumab)","label":"Arm C","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2029-12-30","type":"ESTIMATED"},"conditions":["Breast Cancer; HER2-positive; Metastatic"],"enrollment":{"count":1157,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Trastuzumab deruxtecan","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Taxane","type":"DRUG"},{"name":"Pertuzumab","type":"DRUG"},{"name":"Trastuzumab","type":"DRUG"}],"last_update":"2026-07-30","lead_sponsor":"AstraZeneca","official_title":"Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-11-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment","timeFrame":"Until progression or death, assessed up to approximately 60 months"}],"references":[{"citation":"Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, Saura C, Schneeweiss A, Toi M, Chae YS, Kemal Y, Chaudhari M, Sendur MAN, Yamashita T, Casalnuovo M, Danso MA, Liu J, Shetty J, Herbolsheimer P, Loibl S; DESTINY-Breast09 Trial Investigators. Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2026 Feb 5;394(6):551-562. doi: 10.1056/NEJMoa2508668. Epub 2025 Oct 29.","pmid":"41160818","type":"DERIVED"}],"start_date":{"date":"2021-04-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)","url":"https://clinicaltrials.gov/study/NCT04784715"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04784715"}